DXC Technology (DXC)

NYSEInformation TechnologyInformation Technology ServicesSnapshot 2026-10-23

$16.09+0.06%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge DXC Technology’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q2
EPS	About $0.55non-GAAP	—
FY 2027 · Q3
Revenue	—	3.09B
EPS	—	0.796
FY 2027 · Annual
Revenue	—	12.15B
EPS	$2.4–$2.9non-GAAP	2.59
Free cash flow	About $600M	—
FY 2028 · Annual
Revenue	—	11.95B
EPS	—	2.941

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Free cash flow at least $600 million in fiscal 2027	A primary condition in DXC Technology's published investment case. The stated target is >= $600M.	Under Pressure	Free cash flow falls below $600 million in fiscal 2027	Free cash flow: $359M FY2027-Q1; GAAP. Published target: >= $600M. Target period ends 2027-03-31; this observation covers 2027-Q1. Source published Jul 31, 2026359,000,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2027-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Adjusted EBIT margin ranged from 8.2% in 2026-Q3 to 5.0% in 2027-Q1, showing some margin compression. Management emphasizes disciplined execution and cost efficiency. The trajectory shows mixed margin performance with some decline recently, indicating limited progress on cost efficiency. Delivery assessment Oct 24, 2026
Progress on cost reduction and operational efficiency	A supporting condition in DXC Technology's published investment case. The stated target is Adjusted EBIT margin near 7.6% in 2026-Q4.	Under Pressure	Adjusted EBIT margin falls below 7% in 2026-Q4	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Adjusted EBIT margin ranged from 8.2% in 2026-Q3 to 5.0% in 2027-Q1, showing some margin compression. Management emphasizes disciplined execution and cost efficiency. The trajectory shows mixed margin performance with some decline recently, indicating limited progress on cost efficiency. Delivery assessment Oct 24, 2026
Gross margin near 6.5% in fiscal 2027	It guides revenue near $12.23 billion and EPS around $2.65 for fiscal 2027.	Broken	Gross margin falls below 6% in fiscal 2027	Gross margin: 20.37% FY2027-Q1; GAAP. Published target: 6.5%. Target period ends 2027-03-31; this observation covers 2027-Q1. Source published Jul 31, 202620.373458 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2027-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue near $12.23 billion in fiscal 2027	It guides revenue near $12.23 billion and EPS around $2.65 for fiscal 2027.	Broken	Revenue falls below $12 billion in fiscal 2027	Revenue: $2.999B FY2027-Q1; GAAP. Published target: ~$12.23B. Target period ends 2027-03-31; this observation covers 2027-Q1. Source published Jul 31, 20262,999,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6382675a-3279-40bf-bb64-0929908a4859. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue declined from $3.16B in 2026-Q1 to $3.00B in 2027-Q1, a 5.1% year-over-year decrease. Management consistently emphasizes focus on improving revenue performance despite ongoing organic declines. The trajectory shows persistent revenue decline, indicating limited progress on growth. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPSUnavailable

$3.08 → Unavailable · observed estimates

FY2028 revenueUnavailable

$11.98B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.08	$11,979,315,920	6 / 6
2026-07-25	$3.08	$11,979,315,920	6 / 6
2026-07-26	Unavailable	$11,979,315,917	4 / 5
2026-07-27	$3.08	$11,979,315,920	6 / 6
2026-07-28	$3.08	$11,979,315,920	6 / 6
2026-07-29	Unavailable	$11,979,315,917	4 / 5
2026-07-30	Unavailable	$11,979,315,917	4 / 5
2026-07-31	$3.08	$11,979,315,920	6 / 6
2026-08-01	Unavailable	$11,957,370,786	4 / 5
2026-08-02	$2.99	$11,956,247,970	7 / 7
2026-08-03	Unavailable	$11,956,076,543	4 / 5
2026-08-04	$2.99	$11,956,247,970	7 / 7
2026-08-05	Unavailable	$11,956,076,543	4 / 5
2026-08-06	Unavailable	$11,956,076,543	4 / 5
2026-08-07	Unavailable	$11,956,076,543	4 / 5
2026-08-08	$2.96	$11,988,076,540	7 / 7
2026-08-09	$2.96	$11,988,076,540	7 / 7
2026-08-10	Unavailable	$11,956,076,543	4 / 5
2026-08-11	$2.96	$11,988,076,540	7 / 7
2026-08-12	$2.96	$11,988,076,540	7 / 7
2026-08-13	Unavailable	$11,956,076,543	4 / 5
2026-08-14	Unavailable	$11,956,076,543	4 / 5
2026-08-15	Unavailable	$11,956,076,543	4 / 5
2026-08-16	Unavailable	$11,956,076,543	4 / 5
2026-08-17	Unavailable	$11,956,076,543	4 / 5
2026-08-18	Unavailable	$11,956,076,543	4 / 5
2026-08-19	Unavailable	$11,956,076,543	4 / 5
2026-08-20	Unavailable	$11,987,905,114	4 / 5
2026-08-21	Unavailable	$11,987,905,114	4 / 5
2026-08-22	Unavailable	$11,987,905,114	4 / 5
2026-08-23	Unavailable	$11,987,905,114	4 / 5
2026-08-24	Unavailable	$11,987,905,114	4 / 5
2026-08-25	Unavailable	$11,987,905,114	4 / 5
2026-08-26	Unavailable	$11,987,905,114	4 / 5
2026-08-27	Unavailable	$11,987,905,114	4 / 5
2026-08-28	Unavailable	$11,987,905,114	4 / 5
2026-08-29	Unavailable	$11,987,905,114	4 / 5
2026-08-30	Unavailable	$11,987,905,114	4 / 5
2026-08-31	Unavailable	$11,987,905,114	4 / 5
2026-09-01	Unavailable	$11,987,905,114	4 / 5
2026-09-02	Unavailable	$11,987,905,114	4 / 5
2026-09-03	Unavailable	$11,987,905,114	4 / 5
2026-09-04	Unavailable	$11,987,905,114	4 / 5
2026-09-05	Unavailable	$11,987,905,114	4 / 5
2026-09-06	Unavailable	$11,987,905,114	4 / 5
2026-09-07	Unavailable	$11,987,905,114	4 / 5
2026-09-08	Unavailable	$11,987,905,114	4 / 5
2026-09-09	Unavailable	$11,987,905,114	4 / 5
2026-09-10	Unavailable	$11,987,905,114	4 / 5
2026-09-11	Unavailable	$11,987,905,114	4 / 5
2026-09-12	Unavailable	$11,987,905,114	4 / 5
2026-09-13	Unavailable	$11,987,905,114	4 / 5
2026-09-14	Unavailable	$11,987,905,114	4 / 5
2026-09-15	Unavailable	$11,987,905,114	4 / 5
2026-09-16	Unavailable	$11,987,905,114	4 / 5
2026-09-17	Unavailable	$11,987,905,114	4 / 5
2026-09-18	Unavailable	$11,987,905,114	4 / 5
2026-09-19	Unavailable	$11,987,905,114	4 / 5
2026-09-20	Unavailable	$11,987,905,114	4 / 5
2026-09-21	Unavailable	$11,987,905,114	4 / 5
2026-09-22	Unavailable	$11,987,905,114	4 / 5
2026-09-23	Unavailable	$11,987,905,114	4 / 5
2026-09-24	Unavailable	$11,987,905,114	4 / 5
2026-09-25	Unavailable	$11,987,905,114	4 / 5
2026-09-26	Unavailable	$11,987,905,114	4 / 5
2026-09-27	Unavailable	$11,987,905,114	4 / 5
2026-09-28	Unavailable	$11,987,905,114	4 / 5
2026-09-29	Unavailable	$11,987,905,114	4 / 5
2026-09-30	Unavailable	$11,987,905,114	4 / 5
2026-10-01	Unavailable	$11,987,905,114	4 / 5
2026-10-02	Unavailable	$11,987,905,114	4 / 5
2026-10-03	Unavailable	$11,987,905,114	4 / 5
2026-10-04	Unavailable	$11,987,905,114	4 / 5
2026-10-05	Unavailable	$11,987,905,114	4 / 5
2026-10-06	Unavailable	$11,987,905,114	4 / 5
2026-10-07	Unavailable	$11,987,905,114	4 / 5
2026-10-08	Unavailable	$11,987,905,114	4 / 5
2026-10-09	Unavailable	$11,987,905,114	4 / 5
2026-10-10	Unavailable	$11,987,905,114	4 / 5
2026-10-11	Unavailable	$11,987,905,114	4 / 5
2026-10-12	Unavailable	$11,987,905,114	4 / 5
2026-10-13	Unavailable	$11,987,905,114	4 / 5
2026-10-14	Unavailable	$11,949,576,543	4 / 5
2026-10-15	Unavailable	$11,949,576,543	4 / 5
2026-10-16	Unavailable	$11,949,576,543	4 / 5
2026-10-17	Unavailable	$11,949,576,543	4 / 5
2026-10-18	Unavailable	$11,949,576,543	4 / 5
2026-10-19	Unavailable	$11,949,576,543	4 / 5
2026-10-20	Unavailable	$11,949,576,543	4 / 5
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Hold	Sell*
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 7 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Free cash flow at least $600 million in fiscal 2027Published status: Under Pressure
Progress on cost reduction and operational efficiencyPublished status: Under Pressure
Gross margin near 6.5% in fiscal 2027Published status: Broken
Revenue near $12.23 billion in fiscal 2027Published status: Broken

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-46.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

DXC Technology outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

DXC is a low-valued, execution-sensitive business rather than a clear growth story. Its long-term thesis is intact, with a recent signal turning mildly favorable, but high risk and uneven operating progress temper that view.

What's priced into DXC Technology

The evidence describes DXC as cheap versus peers, while the expectations gap is negative, suggesting the market outlook is cautious. The pricing signal is tagged as justified, with low fragility, but valuation has risen sharply in the recent period.

What the fundamentals likely do

Near term, revenue and adjusted operating margin remain under pressure: revenue declined year over year, and the latest margin was lower than earlier readings. Free cash flow improved in the latest quarter but has been volatile; management has repeatedly prioritized growth and efficiency, with limited progress so far. The latest quarter was a miss, and the evidence also flags a run of consecutive misses, though the estimated miss risk is described as low.

What DXC Technology hinges on

Over the next few quarters, the key company-specific test is whether DXC avoids a guidance cut and makes progress on revenue and cost efficiency. A guidance cut would be a negative signal; continued cash-flow improvement would support the multi-year view. Near-term sector conditions may also matter, including interest-rate changes and results from IBM, ACN, and CTSH.